| Members |
targetComponentId |
| Erwinia salicis |
Brenneria salicis (organism) |
| Erwinia stewartii |
Pantoea stewartii subsp stewartii |
| Erwinia uredovora |
Pantoea ananatis (organism) |
| Erythema infectiosum virus |
Primate erythroparvovirus 1 (organism) |
| erytromycin 250 mg, enterogranulat i kapsel |
Product containing precisely erythromycin 250 milligram/1 each conventional release oral capsule (clinical drug) |
| erytromycin 250 mg, enterokapsel |
Product containing precisely erythromycin 250 milligram/1 each conventional release oral capsule (clinical drug) |
| erytromycin 250 mg, kapsel med modifierad frisättning |
Product containing precisely erythromycin 250 milligram/1 each conventional release oral capsule (clinical drug) |
| Erythromycin ethylsuccinate 100 mg/2.5mL |
Product containing precisely erythromycin (as erythromycin ethylsuccinate) 40 milligram/1 milliliter conventional release oral suspension (clinical drug) |
| Erythromycin ethylsuccinate 100mg/2.5mL oral suspension |
Product containing precisely erythromycin (as erythromycin ethylsuccinate) 40 milligram/1 milliliter conventional release oral suspension (clinical drug) |
| erytromycinetylsuccinat 100 mg/2,5 ml, suspension |
Product containing precisely erythromycin (as erythromycin ethylsuccinate) 40 milligram/1 milliliter conventional release oral suspension (clinical drug) |
| Erythromycin ethylsuccinate 200mg/5mL |
Product containing precisely erythromycin (as erythromycin ethylsuccinate) 40 milligram/1 milliliter conventional release oral suspension (clinical drug) |
| Erythromycin ethylsuccinate 200mg/5mL liquid |
Product containing precisely erythromycin (as erythromycin ethylsuccinate) 40 milligram/1 milliliter conventional release oral suspension (clinical drug) |
| Erythromycin ethylsuccinate 200mg/5mL oral suspension |
Product containing precisely erythromycin (as erythromycin ethylsuccinate) 40 milligram/1 milliliter conventional release oral suspension (clinical drug) |
| erytromycinetylsuccinat 200 mg/5 ml, suspension |
Product containing precisely erythromycin (as erythromycin ethylsuccinate) 40 milligram/1 milliliter conventional release oral suspension (clinical drug) |
| Erythromycin ethylsuccinate 400mg film |
Erythromycin (as erythromycin ethyl succinate) 400 mg oral tablet |
| Erythromycin ethylsuccinate 400mg/5 mL |
Product containing precisely erythromycin (as erythromycin ethylsuccinate) 80 milligram/1 milliliter conventional release oral suspension (clinical drug) |
| Erythromycin ethylsuccinate 400mg/5mL oral suspension |
Product containing precisely erythromycin (as erythromycin ethylsuccinate) 80 milligram/1 milliliter conventional release oral suspension (clinical drug) |
| Erythromycin ethylsuccinate 400mg/5mL powder |
Product containing precisely erythromycin (as erythromycin ethylsuccinate) 80 milligram/1 milliliter conventional release oral suspension (clinical drug) |
| erytromycinetylsuccinat 400 mg/5 ml, suspension |
Product containing precisely erythromycin (as erythromycin ethylsuccinate) 80 milligram/1 milliliter conventional release oral suspension (clinical drug) |
| Erythromycin lactobionate 1g injection (pdr for recon) |
Product containing only erythromycin in parenteral dose form (medicinal product form) |
| erytromycinlaktobionat 1 g, pulver till infusionsvätska, lösning, flaska |
Product containing only erythromycin in parenteral dose form (medicinal product form) |
| Erythromycin lactobionate 500mg |
Product containing precisely erythromycin (as erythromycin lactobionate) 500 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
| Erythromycin lactobionate 500mg injection (pdr for recon) |
Product containing precisely erythromycin (as erythromycin lactobionate) 500 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
| erytromycinlaktobionat 500 mg, pulver till infusionsvätska, lösning, flaska |
Product containing precisely erythromycin (as erythromycin lactobionate) 500 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
| Erythromycin lactobionate 500mg/mL injection |
Product containing precisely erythromycin (as erythromycin lactobionate) 500 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
| Escherichia coli, serotyp O7:H157 |
Escherichia coli serotype O157:H7 (organism) |
| fysostigminsulfat 1,0 %, ögondroppar |
Product containing precisely physostigmine sulfate 10 milligram/1 milliliter conventional release eye solution (clinical drug) |
| esmololhydroklorid 10 mg/ml, infusionsvätska, lösning |
Product containing only esmolol in parenteral dose form (medicinal product form) |
| Esmolol hydrochloride 10mg/mL injection solution ampule |
Product containing only esmolol in parenteral dose form (medicinal product form) |
| esmololhydroklorid 250 mg/ml, injektionskoncentrat, ampull 10 ml |
Esmolol hydrochloride 250 mg/mL solution for injection |
| esmololhydroklorid 250 mg/ml, injektionsvätska, lösning, ampull |
Esmolol hydrochloride 250 mg/mL solution for injection |
| esomeprazol 20 mg, oral suspension med fördröjd frisättning |
Product containing precisely esomeprazole (as esomeprazole magnesium) 20 milligram/1 sachet granules for conventional release oral suspension (clinical drug) |
| esomeprazol 40 mg, oral suspension med fördröjd frisättning |
Product containing precisely esomeprazole 40 milligram/1 sachet granules for conventional release oral suspension (clinical drug) |
| esomeprazolmagnesium 20 mg + naproxen 375 mg, tablett med fördröjd frisättning |
Product containing precisely esomeprazole (as esomeprazole magnesium) 20 milligram and naproxen (as naproxen sodium) 375 milligram/1 each gastro-resistant oral tablet (clinical drug) |
| esomeprazolmagnesium 20 mg + naproxen 500 mg, tablett med fördröjd frisättning |
Product containing precisely esomeprazole (as esomeprazole magnesium) 20 milligram and naproxen 500 milligram/1 each gastro-resistant oral tablet (clinical drug) |
| esomeprazolmagnesium 20 mg, enterokapsel |
Esomeprazole (as esomeprazole magnesium) 20 mg oral capsule |
| esomeprazolmagnesium 20 mg, kapsel med modifierad frisättning |
Esomeprazole (as esomeprazole magnesium) 20 mg oral capsule |
| esomeprazolmagnesium 40 mg, enterokapsel |
Esomeprazole (as esomeprazole magnesium) 40 mg oral capsule |
| esomeprazolmagnesium 40 mg, kapsel med modifierad frisättning |
Esomeprazole (as esomeprazole magnesium) 40 mg oral capsule |
| Esophageal motility disorder |
Diffuse spasm of esophagus |
| Esophagospasm |
Diffuse spasm of esophagus |
| Essential thrombocythaemia |
Essential thrombocythemia (disorder) |
| Estimated creatine clearance |
Estimated creatinine clearance |
| uppskattad kreatininclearance |
Estimated creatinine clearance |
| Estimated creatine clearance |
Estimated creatinine clearance |
| beräknat förlossningsdatum efter senaste normala menstruation |
Estimated date of delivery from last period |
| uppskattat totalt energiintag |
Estimated quantity of intake of energy in 24 hours (observable entity) |
| Estradiol |
Estradiol |
| Estradiol + norethindrone acetate 0.62mg/2.7mg |
Estradiol 2.08 microgram/hour and norethisterone acetate 5.83 microgram/hour prolonged-release transdermal patch |
| estradiol 0,025 mg/dag, plåster |
Estradiol 1.04 microgram/hour prolonged-release transdermal patch |
| Estradiol 0.025mg/unt |
Estradiol 1.04 microgram/hour prolonged-release transdermal patch |
| Estradiol 0.0375mg/day |
Estradiol 1.56 microgram/hour prolonged-release transdermal patch |
| estradiol 0,375 mg/dag, plåster |
Estradiol 1.56 microgram/hour prolonged-release transdermal patch |
| Estradiol 0.05 mg/day |
Product containing precisely estradiol 2.08 microgram/1 hour prolonged-release transdermal patch (clinical drug) |
| Estradiol 0.05mg/24 hr |
Product containing precisely estradiol 2.08 microgram/1 hour prolonged-release transdermal patch (clinical drug) |
| Estradiol 0.05mg/day |
Product containing precisely estradiol 2.08 microgram/1 hour prolonged-release transdermal patch (clinical drug) |
| estradiol 0,05 mg/dag, plåster |
Product containing precisely estradiol 2.08 microgram/1 hour prolonged-release transdermal patch (clinical drug) |
| estradiol 0,05 mg + noretindronacetat 0,14 mg/dag, depåplåster |
Estradiol 2.08 microgram/hour and norethisterone acetate 5.83 microgram/hour prolonged-release transdermal patch |
| estradiol 0,05 mg + noretindronacetat 0,25 mg/dag, depåplåster |
Product containing precisely estradiol 2.08 microgram/1 hour and norethisterone acetate 10.4 microgram/1 hour prolonged-release transdermal patch (clinical drug) |
| estradiol 0,06 mg/dag, depåplåster |
Estradiol 2.5 microgram/hour prolonged-release transdermal patch |
| Estradiol 0.075mg/day |
Estradiol 3.13 microgram/hour prolonged-release transdermal patch |
| estradiol 0,075 mg/dag, plåster |
Estradiol 3.13 microgram/hour prolonged-release transdermal patch |
| Estradiol 0.1mg/day |
Product containing precisely estradiol 4.167 microgram/1 hour prolonged-release transdermal patch (clinical drug) |
| estradiol 0,1 mg/dag, plåster |
Product containing precisely estradiol 4.167 microgram/1 hour prolonged-release transdermal patch (clinical drug) |
| estradiol 14 mikrogram/dag, depåplåster |
Estradiol 583 nanogram/hour prolonged-release transdermal patch |
| estradiol 25 mikrogram, vaginalinlägg |
Product containing precisely estradiol 25 microgram/1 each conventional release vaginal tablet (clinical drug) |
| Estradiol 3.9mg/patch |
Product containing precisely estradiol 2.08 microgram/1 hour prolonged-release transdermal patch (clinical drug) |
| Estradiol 5.75mg |
Estradiol 3.13 microgram/hour prolonged-release transdermal patch |
| Estradiol 5.85mg |
Estradiol 3.13 microgram/hour prolonged-release transdermal patch |
| östradiolimplantatallergi |
Allergy to estradiol (finding) |
| Ethanoic acid |
Acetic acid |
| etanolaminoleat 5 %, injektionslösning, ampull |
Product containing only ethanolamine in parenteral dose form (medicinal product form) |
| Ether hydrolase |
Ether hydrolase |
| biverkning av eteranestetika |
Adverse reaction to inhaled anesthetic with ether structure |
| allergi mot anestesimedel, eter |
Allergy to substance with ether structure |
| etinylestradiol 0,02 mg + norelgestromin 0,15 mg per dygn, depåplåster |
Ethinylestradiol 1.46 microgram/hour and norelgestromin 6.25 microgram/hour prolonged-release transdermal patch |
| Ethnic form of nose - finding |
Finding of appearance of nose |
| Ethnic group not given - patient refused |
Refusal by patient to provide information about ethnic group |
| patienten har nekat att lämna information om etnisk tillhörighet |
Refusal by patient to provide information about ethnic group |
| Ethnic group not given - patient refused |
Refusal by patient to provide information about ethnic group |
| etylenoxidspecifikt extrakt |
Product containing ethylene oxide (medicinal product) |
| Ethynodiol diacetate [progestogen oral contraceptive] |
Product containing etynodiol (medicinal product) |
| etynodioldiacetatallergi |
Allergy to progestational hormone |
| Ethynodiol diacetate preparation |
Product containing etynodiol (medicinal product) |
| Etidocaine hydrochloride 1% injection |
Product containing precisely etidocaine hydrochloride 10 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| etidokainhydroklorid 1 %, injektionsvätska, lösning, ampull |
Product containing precisely etidocaine hydrochloride 10 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Etidocaine hydrochloride+epinephrine 1%/1:200000 injection |
Product containing precisely epinephrine (as epinephrine bitartrate) 5 microgram/1 milliliter and etidocaine hydrochloride 10 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Etidocaine hydrochloride+epinephrine 1.5%/1:200000 injection |
Product containing precisely epinephrine (as epinephrine bitartrate) 5 microgram/1 milliliter and etidocaine hydrochloride 15 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| etidokainhydroklorid 1,5 % + adrenalin 1:200 000, injektionsvätska, lösning, flaska 20 ml |
Product containing precisely epinephrine (as epinephrine bitartrate) 5 microgram/1 milliliter and etidocaine hydrochloride 15 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| etidokainhydroklorid 1,5 % + adrenalin 1:200 000, injektionsvätska, lösning, flaska 2 ml |
Product containing precisely epinephrine (as epinephrine bitartrate) 5 microgram/1 milliliter and etidocaine hydrochloride 15 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Etidronate |
Product containing etidronic acid (medicinal product) |
| etodolak 400 mg, tablett med modifierad frisättning |
Product containing only etodolac in oral dose form (medicinal product form) |
| etodolak 400 mg, depåtablett |
Product containing only etodolac in oral dose form (medicinal product form) |
| etodolak 500 mg, tablett med modifierad frisättning |
Product containing only etodolac in oral dose form (medicinal product form) |
| etodolak 500 mg, depåtablett |
Product containing only etodolac in oral dose form (medicinal product form) |
| etonogestrel 68 mg, subdermalt implantat |
Product containing precisely etonogestrel 68 milligram/1 each prolonged-release subcutaneous implant (clinical drug) |
| etonogestrel-frisättande implantat |
Etonogestrel-containing product in parenteral dose form |
| etoposid 100 mg/5 ml, injektionsvätska, lösning |
Etoposide only product in parenteral dose form |
| Etoposide 100mg/5mL injection |
Etoposide only product in parenteral dose form |
| etoposid 100 mg/5 ml, injektionskoncentrat |
Etoposide only product in parenteral dose form |
| Etoposide 100mg/5mL powder for injection 5mL vial |
Etoposide only product in parenteral dose form |
FHIR